Shannon Thyme Klinger - Feb 27, 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Legal Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 27, 2024
Transactions value $
$0
Form type
4
Date filed
2/29/2024, 04:37 PM
Previous filing
Dec 11, 2023
Next filing
Mar 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRNA Common Stock 7.91K Feb 27, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +23.6K $0.00 23.6K Feb 27, 2024 Common Stock 23.6K $96.20 Direct F1
transaction MRNA Restricted Stock Units Award $0 +12.4K $0.00 12.4K Feb 27, 2024 Common Stock 12.4K $0.00 Direct F2
transaction MRNA Stock Option (Right to Buy) Award $0 +60.2K $0.00 60.2K Feb 27, 2024 Common Stock 60.2K $96.20 Direct F3
transaction MRNA Restricted Stock Units Award $0 +10.6K $0.00 10.6K Feb 27, 2024 Common Stock 10.6K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 50% of this option will vest and become exercisable on February 27, 2026 and the remaining 50% will vest and become exercisable on February 27, 2027, subject to the recipient's continued service.
F4 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.